MYGN

6.02

3.44% 0.20

Pre-mercato: 6.05 0.03 +0.50%

Myriad Genetics Inc (MYGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$5.82

Aprire:

$5.82

Volume 24 ore:

1.49M

Relative Volume:

0.34

Capitalizzazione di mercato:

$575.81M

Reddito:

$829.00M

Utile/perdita netta:

$-399.90M

Rapporto P/E:

-1.3948

EPS:

-4.3159

Flusso di cassa netto:

$-23.20M

1 W Prestazione:

+8.66%

1M Prestazione:

+44.36%

6M Prestazione:

+24.64%

1 anno Prestazione:

-25.68%

Intervallo 1D:

$0.00

Intervallo di 1 settimana:

$5.39

$6.07

Portata 52W:

$2.74

$8.50

Myriad Genetics Inc Stock (MYGN) Company Profile

Nome

Myriad Genetics Inc

Settore

Healthcare (1053)

Industria

Diagnostics & Research (44)

Telefono

801-584-3600

Indirizzo

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Dipendente

2,700

Cinguettio

@myriadgenetics

Prossima data di guadagno

2026-11-04

Ultimi documenti SEC

MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, NTRA, A, IQV

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MYGN Myriad Genetics Inc	6.02	575.81M	829.00M	-399.90M	-23.20M	-4.3159
TMO Thermo Fisher Scientific Inc	684.89	253.24B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	232.97	163.77B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	404.90	58.36B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	175.96	49.61B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	273.60	45.03B	16.63B	1.39B	2.12B	8.0674

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-10-20	Aggiornamento	Piper Sandler	Underweight → Neutral
2026-09-09	Ripresa	UBS	Neutral
2026-09-01	Downgrade	Piper Sandler	Overweight → Underweight
2025-05-21	Downgrade	Scotiabank	Sector Outperform → Sector Perform
2025-05-08	Downgrade	Wolfe Research	Outperform → Peer Perform
2025-05-07	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-04-09	Downgrade	Guggenheim	Buy → Neutral
2025-03-12	Aggiornamento	Piper Sandler	Neutral → Overweight
2025-02-12	Iniziato	Craig Hallum	Buy
2024-12-10	Iniziato	UBS	Neutral
2024-12-09	Downgrade	Leerink Partners	Outperform → Market Perform
2024-09-19	Iniziato	Morgan Stanley	Equal-Weight
2024-08-28	Iniziato	Wells Fargo	Overweight
2024-06-27	Iniziato	Scotiabank	Sector Outperform
2024-06-03	Ripresa	Jefferies	Underperform
2024-05-08	Aggiornamento	Leerink Partners	Market Perform → Outperform
2023-12-21	Ripresa	Piper Sandler	Neutral
2023-12-19	Iniziato	Wells Fargo	Equal Weight
2023-12-14	Iniziato	Guggenheim	Buy
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-07-05	Ripresa	JP Morgan	Underweight
2023-05-23	Aggiornamento	Goldman	Sell → Buy
2023-01-18	Aggiornamento	Raymond James	Mkt Perform → Outperform
2022-10-06	Iniziato	Stephens	Equal-Weight
2021-10-15	Ripresa	Cowen	Market Perform
2021-06-15	Iniziato	Raymond James	Mkt Perform
2021-06-03	Iniziato	Goldman	Sell
2019-09-26	Downgrade	BofA/Merrill	Neutral → Underperform
2019-08-14	Downgrade	Piper Jaffray	Overweight → Neutral
2019-08-02	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-08-01	Aggiornamento	Barclays	Underweight → Equal Weight
2019-07-29	Downgrade	Needham	Strong Buy → Hold
2019-07-09	Downgrade	Cowen	Outperform → Market Perform
2019-03-12	Reiterato	Needham	Strong Buy
2019-01-03	Iniziato	Needham	Strong Buy
2018-11-30	Aggiornamento	Goldman	Sell → Neutral
2018-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2018-07-11	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	Iniziato	Goldman	Sell
2018-01-22	Reiterato	Barclays	Equal Weight
2018-01-05	Iniziato	BTIG Research	Buy
2017-10-02	Ripresa	Leerink Partners	Mkt Perform
2017-08-09	Reiterato	Barclays	Equal Weight
2017-02-08	Aggiornamento	Ladenburg Thalmann	Sell → Neutral
2017-01-18	Iniziato	Deutsche Bank	Sell
2016-10-10	Downgrade	Ladenburg Thalmann	Neutral → Sell

Mostra tutto

Myriad Genetics Inc Borsa (MYGN) Ultime notizie

Oct 22, 2026

Labcorp to buy Myriad’s prenatal health testing unit for $210M - MedTech Dive

Oct 22, 2026

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers - The Manila Times

Oct 22, 2026

Myriad Genetics presents data on cancer recurrence detection test By Investing.com - Investing.com Canada

Oct 22, 2026

Myriad Genetics releases MRD cancer detection data at ESMO 2026 - StreetInsider

Oct 22, 2026

Myriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions - Yahoo Finance

Oct 22, 2026

Myriad Genetics: Prenatal Sale Provides A Lifeline In A Tough Spot (NASDAQ:MYGN) - Seeking Alpha

Oct 22, 2026

Oct 21, 2026

Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner - Yahoo Finance

Oct 21, 2026

Myriad Genetics to present at Wells Fargo healthcare conference - scanx.trade

Oct 21, 2026